<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The pandemic of" exact="coronavirus disease 2019" post="(COVID-19), with rising numbers of patients worldwide, presents an"/>
 <result pre="pharmacological strategies, based on our present understanding of SARS-CoV and" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) infections. Finally, we outline clinical trials currently"/>
 <result pre="three epidemics of lethal diseases: severe acute respiratory syndrome (SARS)," exact="Middle East respiratory syndrome" post="(MERS) and COVID-19. SARS-CoV-2 seems to be less virulent"/>
 <result pre="endocytosis has not been identified [23]. The initial step during" exact="SARS-CoV-2 infection" post="is the binding of S to its host receptors,"/>
 <result pre="interferon (IFN)-Î± and IFN-Î², determine the innate immune response to" exact="SARS-CoV-2 infection" post="[35]. Pathogen associated molecular patterns (PAMPs) such as viral"/>
 <result pre="TNF-Î±), which have been reported to be overexpressed significantly in" exact="SARS-CoV-2 infection" post="in association with â€œcytokine stormâ€� [37,38]. TI IFNs and"/>
 <result pre="CD8+ T cells are cytotoxic to virus-infected cells [53]. During" exact="SARS-CoV infection," post="the majority (approximately 80%) of inflammatory cells infiltrating the"/>
 <result pre="CD8+ cells to infection by MERS-CoV and SARS-CoV [56]. During" exact="SARS-CoV-2 infection," post="a reduction in the number and quality of CD4+"/>
 <result pre="role of IL-17 and related altered cytokines are highlighted in" exact="SARS-CoV-2 infection" post="[57]. One of the important methods that SARS-CoV-2 may"/>
 <result pre="and morbidity of COVID-19 [70]. CRS is not specific to" exact="SARS-CoV-2 infection" post="and has been demonstrated for MERS-CoV and SARS-CoV, as"/>
 <result pre="COVID-19 outcomes will help researchers to understand the pathophysiology of" exact="SARS-CoV-2 infection" post="and its interactions with underlying chronic diseases. Early clinical"/>
 <result pre="Remdesivir Remdesivir (RDV) was originally developed as a treatment for" exact="Ebola" post="and Marburg virus infection and is a promising candidate"/>
 <result pre="E6 cells has shown that remdesivir at low-micromolar concentrations blocks" exact="SARS-CoV-2 infection" post="with high selectivity (half-maximal effective concentration (EC50), 0.77 Î¼M;"/>
 <result pre="et al. reported a clinical trial including 199 patients with" exact="SARS-CoV-2 infection," post="which showed that LPV/r was not associated with clinical"/>
 <result pre="been used as a therapeutic agent against respiratory syncytial virus," exact="Lassa fever" post="virus, influenza A and B and in combination with"/>
 <result pre="of ribavirin and LPV/r in combination with interferon alpha-1b for" exact="SARS-CoV-2 infection" post="[132]. 8.1.5. Arbidol Hydrochloride (Umifenovir) Arbidol (ARB; ethyl-6-bromo-4-[(dimethylamino) methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-indole-3-carboxylate"/>
 <result pre="one study from Wuhan in 67 hospitalized patients with confirmed" exact="SARS-CoV-2 infection," post="36 (53.7%) received arbidol treatment for a median duration"/>
 <result pre="TMPRSS2 [142]. Additionally, the effect of camostat mesylate in blocking" exact="SARS-CoV-2 infection" post="of human lung Calu-3 cells has been demonstrated [143]."/>
 <result pre="effect of gabexate mesylate, nafamostat mesylate and camostat mesylate on" exact="SARS-CoV-2 infection" post="and demonstrated that nafamostat mesylate inhibited S-mediated entry of"/>
 <result pre="rabies virus, hepatitis A virus, poliovirus, Chikungunya virus, Lassa virus," exact="Dengue" post="virus, Hendra and Nipah viruses, Crimeanâ€&quot;Congo hemorrhagic fever virus,"/>
 <result pre="and Nipah viruses, Crimeanâ€&quot;Congo hemorrhagic fever virus, Zika virus and" exact="Ebola" post="virus, as well as HBV and herpes simplex virus"/>
 <result pre="were evaluated in Vero E6; chloroquine was effective in controlling" exact="SARS-CoV-2 infection" post="in vitro with an EC50 at 48 h of"/>
 <result pre="in the U.S. (NCT04308668) as a post-exposure prophylaxis/preemptive therapy for" exact="SARS-CoV-2 infection." post="Recently the NIH guidelines panel for COVID-19 treatment recommended"/>
 <result pre="(DENV), West Nile Virus, Venezuelan equine encephalitis virus (VEEV) and" exact="Influenza" post="virus [166]. Ivermectin inhibits the interaction between the integrase"/>
 <result pre="in humans [169]. Overall, the possible efficacy of ivermectin against" exact="SARS-CoV-2 infection" post="needs data to support it. 9. Immunotherapy Several studies"/>
 <result pre="Previous coronavirus outbreaks including SARS-CoV and MERS-CoV as well as" exact="Ebola" post="virus disease, avian influenza A (H5N1), 2009 H1N1 pandemic"/>
 <result pre="convalescent serum [173,174]. However, convalescent plasma was not successful for" exact="Ebola" post="[175]. Patients with SARS-CoV-2 infection develop a serum antibody"/>
 <result pre="convalescent plasma was not successful for Ebola [175]. Patients with" exact="SARS-CoV-2 infection" post="develop a serum antibody response (IgG) to different epitopes"/>
 <result pre="derived from memory B cells from an individual convalescing from" exact="SARS-CoV infection" post="are also capable of neutralizing SARS-CoV-2 [213]. By screening"/>
 <result pre="humanized mAb, which in cell culture was able to block" exact="SARS-CoV-2 infection" post="[214]. In another study, four mAbs were isolated from"/>
 <result pre="Previous studies have suggested an antiviral function for azithromycin in" exact="Ebola" post="virus infection, both in vitro and in mice [216]."/>
 <result pre="Interestingly, Tran et al. reported antiviral activity of azithromycin against" exact="Influenza" post="(H1N1) virus; treatment prior to infection inhibited virus replication"/>
 <result pre="storm are two important aspects of the pathogenesis in severe" exact="SARS-CoV-2 infection" post="[222]. However, a meta-analysis of previous observational studies revealed"/>
 <result pre="Interest The authors declare no conflict of interest. Abbreviations COVID-19" exact="Coronavirus disease 2019" post="SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 FDA US"/>
 <result pre="syndrome coronavirus 2 FDA US Food and Drug Administration MERS-CoV" exact="Middle East respiratory syndrome" post="coronavirus ARDS acute respiratory distress syndrome RSCU synonymous codon"/>
 <result pre="AssayAntimicrob. Agents Chemother.2016606532653910.1128/AAC.01043-1627550352 23.GuoY.-R.CaoQ.-D.HongZ.TanY.-Y.ChenS.JinH.TanK.S.WangD.Y.YanY.The origin, transmission and clinical therapies on" exact="coronavirus disease 2019" post="(COVID-19) outbreakâ€&quot;An update on the statusMil. Med. Res.202071111010.1186/s40779-020-00240-032169119 24.AstutiI.J.D.Research"/>
 <result pre="J. Allergy Immunol2020381932105090 28.BourgonjeA.R.AbdulleA.E.TimensW.HillebrandsJ.L.NavisG.J.GordijnS.J.Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of" exact="coronavirus disease 2019" post="(COVID-19)J. Pathol.202010.1002/path.5471 29.SpiegelM.WeberF.Inhibition of cytokine gene expression and induction"/>
 <result pre="Treatment and Preventive Strategies in COVID-19Vaccines2020822410.3390/vaccines802022432423059 60.XuJ.JiaW.WangP.ZhangS.ShiX.WangX.ZhangL.-Q.WangT.GoldingH.KhuranaS.Antibodies and vaccines against" exact="Middle East respiratory syndrome" post="coronavirusEmerg. Microbes Infect.2019884185610.1080/22221751.2019.162448231169078 61.RavichandranS.CoyleE.M.KlenowL.TangJ.GrubbsG.LiuS.WangT.GoldingH.KhuranaS.Antibody signature induced by SARS-CoV-2 spike"/>
 <result pre="the Greater Toronto AreaJAMA2003289280110.1001/jama.289.21.JOC3088512734147 89.AlqahtaniF.Y.AleanizyF.MohamedR.A.E.H.AlanaziM.S.MohamedN.AlrasheedM.M.AbanmyN.AlhawassiT.Prevalence of comorbidities in cases of" exact="Middle East respiratory syndrome" post="coronavirus: A retrospective studyEpidemiol. Infect.20181471510.1017/S095026881800292330394248 90.The Centers for Disease"/>
 <result pre="al.Case of the index patient who caused tertiary transmission of" exact="coronavirus disease 2019" post="in Korea: The application of lopinavir/ritonavir for the treatment"/>
 <result pre="Sci.202035e7910.3346/jkms.2020.35.e7932056407 111.WangZ.ChenX.LuY.ChenF.ZhangW.Clinical characteristics and therapeutic procedure for four cases with" exact="2019 novel coronavirus pneumonia" post="receiving combined Chinese and Western medicine treatmentBiosci. Trends202014646810.5582/bst.2020.0103032037389 112.YoungB.E.OngS.W.X.KalimuddinS.LowJ.G.TanS.Y.LohJ.NgO.-T.MarimuthuK.AngL.W.MakT.M.et"/>
 <result pre="Med. Virol.20057714715010.1002/jmv.2043116121363 175.Van GriensvenJ.EdwardsT.De LamballerieX.SempleM.G.GallianP.BaizeS.HorbyP.RaoulH.MagassoubaN.AntierensA.et al.Evaluation of Convalescent Plasma for" exact="Ebola" post="Virus Disease in GuineaN. Engl. J. Med.2016374334210.1056/NEJMoa151181226735992 176.AnudeepT.JeyaramanM.ShettyD.U.RajH.AjayS.Rajeswari SomasundaramV.K.V.KumarV.JainR.ShirodkarJ.Convalescent"/>
 <result pre="binding to its receptor ACE2Science20203681274127810.1126/science.abc224132404477 216.SweitiH.EkwunifeO.JaschinskiT.LhachimiS.K.Repurposed Therapeutic Agents Targeting the" exact="Ebola" post="Virus: A Systematic ReviewCurr. Ther. Res.201784102110.1016/j.curtheres.2017.01.00728761574 217.GielenV.JohnstonS.L.EdwardsM.R.Azithromycin induces anti-viral"/>
 <result pre="systematic review and meta-analysisJ. Infect.202081e13e2010.1016/j.jinf.2020.03.06232283144 226.ZhaL.LiS.PanL.TefsenB.LiY.FrenchN.ChenL.YangG.VillanuevaE.V.Corticosteroid treatment of patients with" exact="coronavirus disease 2019" post="(COVID -19)Med. J. Aust.202021241642010.5694/mja2.5057732266987 227.FangX.MeiQ.YangT.LiL.WangY.TongF.GengS.PanA.Low-dose corticosteroid therapy does not"/>
 <result pre="the Pandemic Coronavirus Disease 2019 (COVID-19)Cureus20201210.7759/cureus.7560 238.DongL.HuS.GaoJ.Discovering drugs to treat" exact="coronavirus disease 2019" post="(COVID-19)Drug Discov. Ther.202014586010.5582/ddt.2020.0101232147628 239.SandersJ.M.MonogueM.L.JodlowskiT.Z.CutrellJ.B.Pharmacologic Treatments for Coronavirus Disease 2019"/>
 <result pre="diameter with a 26â€&quot;32 kb single stranded RNA (ssRNA) genome." exact="Severe acute respiratory syndrome" post="coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and"/>
 <result pre="stranded RNA (ssRNA) genome. Severe acute respiratory syndrome coronavirus (SARS-CoV)," exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2"/>
 <result pre="red cross. ijms-21-05559-t001_Table 1Table 1 List of available drugs targeting" exact="SARS-CoV-2 infection" post="and their effective dosage. Name of Medicine Target Classification"/>
</results>
